Last reviewed · How we verify
Sodium Chloride 0.9% Inj
Sodium chloride 0.9% is an isotonic saline solution that replaces fluid and electrolyte losses to maintain osmotic balance and hydration.
Sodium chloride 0.9% is an isotonic saline solution that replaces fluid and electrolyte losses to maintain osmotic balance and hydration. Used for Fluid and electrolyte replacement in dehydration, Maintenance of intravascular volume in perioperative and critical care settings, Vehicle for intravenous drug administration.
At a glance
| Generic name | Sodium Chloride 0.9% Inj |
|---|---|
| Also known as | Preemptive Sodium Chloride 0.9%, Normal saline, Solution for Injection, Placebo, normal saline |
| Sponsor | Dalarna County Council, Sweden |
| Drug class | Crystalloid fluid / Electrolyte replacement |
| Modality | Small molecule |
| Therapeutic area | Fluid and Electrolyte Management |
| Phase | FDA-approved |
Mechanism of action
This solution contains sodium and chloride ions in physiologic concentrations (0.9% w/v) that match blood plasma osmolality, making it isotonic. It is used intravenously to restore intravascular volume, replace electrolytes lost through dehydration or bleeding, and serve as a vehicle for drug administration. The solution does not alter serum electrolyte concentrations when administered in normal quantities.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Maintenance of intravascular volume in perioperative and critical care settings
- Vehicle for intravenous drug administration
Common side effects
- Hyperchloremic acidosis (with large volume administration)
- Fluid overload / pulmonary edema (in susceptible patients)
- Hypernatremia (with excessive administration)
- Phlebitis at infusion site
Key clinical trials
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections (PHASE3)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (PHASE3)
- Analgesic Effect of IntraPeritoneal LIGNOcaine in Gynaecological Open Surgery (NA)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis (NA)
- Botulinum Toxin Injection in the UES for R-CPD (PHASE4)
- Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Chloride 0.9% Inj CI brief — competitive landscape report
- Sodium Chloride 0.9% Inj updates RSS · CI watch RSS
- Dalarna County Council, Sweden portfolio CI